The CSL Ltd (ASX: CSL) share price fall has become too big for investors to ignore.
The biotech giant is down another 1.46% to $97.81 on Thursday, taking its one-month decline to about 26%.
Over the past year, the damage is even more severe. CSL shares have fallen roughly 60% since this time last year.
That’s a rare fall for a business long viewed as one of the ASX’s highest-quality healthcare names.
Now, after months of bad news, investors have been given a small but interesting signal from inside the company.
Let’s take a closer look.
Image source: Getty Images
Naylor buys after the sell-off
According to the company’s change of director’s interest notice, interim Chief Executive Gordon Naylor…
